Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02966873 · ClinicalTrials.gov registry record · Phase 2

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

A Phase 2 study, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
182
Enrollment target

NCT02966873 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 182 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02966873, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
182 participants
Enrollment target

Study Summary

This is a randomized controlled Phase II clinical trial designed to evaluate the effects of N-acetylcysteine (NAC) in reducing Alcohol Use Disorder (AUD) severity and Post Traumatic Stress Disorder (PTSD) symptomatology among individuals with current AUD and PTSD.

Interventions

  • BEHAVIORAL Cognitive Behavioral Therapy (CBT)
  • OTHER Functional magnetic resonance imaging (fMRI)
  • DRUG N-Acetylcysteine (NAC) Treatment
  • DRUG Inactive Placebo Oral Capsule
  • OTHER Proton magnetic resonance spectroscopy (MRS) Imaging

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2016-10-01
Est. Completion 2022-09-19
Phase Phase 2

What the Registry Record Tells You About NCT02966873

The ClinicalTrials.gov registry entry for NCT02966873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Cognitive Behavioral Therapy (CBT) is the first listed.

NCT02966873 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02966873 about?

NCT02966873 is a clinical study titled "Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)". This is a randomized controlled Phase II clinical trial designed to evaluate the effects of N-acetylcysteine (NAC) in reducing Alcohol Use Disorder (AUD) severity and Post Traumatic Stress Disorder (PTSD) symptomatology among individuals with current AUD and PTSD.

What is the current status of trial NCT02966873?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2016-10-01. Estimated completion is 2022-09-19.

What interventions are being tested in trial NCT02966873?

The interventions under investigation include: Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Functional magnetic resonance imaging (fMRI) (OTHER), N-Acetylcysteine (NAC) Treatment (DRUG), Inactive Placebo Oral Capsule (DRUG), Proton magnetic resonance spectroscopy (MRS) Imaging (OTHER).

Who is sponsoring clinical trial NCT02966873?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.